Literature DB >> 1808046

Neonatal septicemia: a reappraisal with special reference to the use of cefotaxime.

U Vaidya1, S Bhave, V Hegde, A N Pandit.   

Abstract

In a study period of one year, 381 babies (38.7% of all nursery admissions) were clinically diagnosed to have sepsis. Of these, 156 (40.9%) had positive blood cultures. Klebsiella was by far the commonest organism isolated (41%) followed by other Gram negative organisms. Gram positive organisms were uncommon (8%). Sensitivity of Gram negative organisms was poor to penicillin (11%) and ampicillin (18%); significantly better to kanamycin (65%), gentamicin (74%) and best to cefotaxime (79%). Only 8% isolates were resistant to all antibiotics. Combination of cefotaxime and gentamicin was effective against 90% of the isolates (in vitro) as compared to 74% for gentamicin and ampicillin. In vivo, mortality in the cefotaxime treated group was significantly lower (24.3%) than control group (47%) although both groups were clinically and bacteriologically comparable (p less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1808046

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  3 in total

1.  Neonatal gram-negative bacteremia.

Authors:  S G Joshi; V S Ghole; K B Niphadkar
Journal:  Indian J Pediatr       Date:  2000-01       Impact factor: 1.967

2.  Comparative Study in Early Neonates with Septicemia by Blood Culture, Staining Techniques and C - Reactive Protein (CRP).

Authors:  V Dhanalakshmi; E Suguna Sivakumar
Journal:  J Clin Diagn Res       Date:  2015-03-01

3.  Epidemiology of bacteremia in young hospitalized infants in Vientiane, Laos, 2000-2011.

Authors:  Margot Anderson; Khonesavanh Luangxay; Kongkham Sisouk; Latdavan Vorlasan; Bandith Soumphonphakdy; Vanmaly Sengmouang; Vilada Chansamouth; Koukeo Phommasone; Russell Van Dyke; Euming Chong; David A B Dance; Rattanaphone Phetsouvanh; Paul N Newton
Journal:  J Trop Pediatr       Date:  2013-07-31       Impact factor: 1.165

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.